Stryker Corporation (SYK) To Go Ex-Dividend on September 30th

Stryker Corporation (NYSE:SYK) declared a quarterly dividend on Thursday, August 7th, RTT News reports. Shareholders of record on Tuesday, September 30th will be given a dividend of 0.84 per share by the medical technology company on Friday, October 31st. This represents a c) annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th.

Stryker has a payout ratio of 22.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Stryker to earn $14.83 per share next year, which means the company should continue to be able to cover its $3.36 annual dividend with an expected future payout ratio of 22.7%.

Stryker Stock Up 0.1%

Stryker stock opened at $368.83 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market cap of $141.01 billion, a PE ratio of 48.85, a P/E/G ratio of 2.66 and a beta of 0.93. Stryker has a twelve month low of $329.16 and a twelve month high of $406.19. The firm’s 50 day moving average price is $385.71 and its two-hundred day moving average price is $379.08.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts predict that Stryker will post 13.47 EPS for the current fiscal year.

Insider Buying and Selling at Stryker

In related news, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Stryker

Several large investors have recently bought and sold shares of the stock. Consolidated Portfolio Review Corp raised its stake in Stryker by 4.2% during the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after purchasing an additional 26 shares during the last quarter. Princeton Global Asset Management LLC raised its stake in shares of Stryker by 16.9% in the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock valued at $71,000 after buying an additional 26 shares in the last quarter. Sunflower Bank N.A. raised its stake in shares of Stryker by 4.0% in the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after buying an additional 27 shares in the last quarter. Pitti Group Wealth Management LLC raised its stake in shares of Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after buying an additional 27 shares in the last quarter. Finally, Sachetta LLC raised its stake in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.